NEW YORK (GenomeWeb News) – Roche subsidiary Genentech will use Horizon Discovery's mutant-and-normal cell lines in its oncology drug research programs under a three year agreement, Horizon said today.

The agreement, which expands an ongoing relationship between the companies, will give Genentech access to Horizon's X-MAN cell-line library.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.